Experimental drug combo targets sarcoma before surgery
NCT ID NCT05116254
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a drug called AZD1390, which blocks DNA repair, given with or without an immunotherapy (durvalumab) plus standard radiation before surgery for soft tissue sarcoma. The goal was to see if the combination is safe and tolerable, especially regarding wound healing after surgery. Only 12 people took part, and the study was stopped early, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD1390 (a drug that blocks DNA repair) combined with radiotherapy, and sometimes with durvalumab (an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for soft tissue sarcoma that combines targeted drugs with standard radiotherapy.
What could go wrong
This was a very early (Phase 1) trial that was terminated early with only 12 participants. The combination may cause significant side effects, especially wound healing problems after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antoni van Leeuwenhoek
Amsterdam, 1066CX, Netherlands